Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders.

Autor: Rahmati-Dehkordi F; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.; Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran., Khanifar H; Department of Internal Medicine, Shahre-kord University of Medical Sciences, Shahre-kord, Iran., Najari N; Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.; Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran., Tamtaji Z; Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran., Talebi Taheri A; Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.; Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Aschner M; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA., Shafiee Ardestani M; Department of Radio Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran., Mirzaei H; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran., Dadgostar E; Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ehsandadgostar71@gmail.com.; Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran. ehsandadgostar71@gmail.com., Nabavizadeh F; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Nabavizadeh@tums.ac.ir.; Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Nabavizadeh@tums.ac.ir., Tamtaji OR; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. tamtaji.or@gmail.com.; Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. tamtaji.or@gmail.com.
Jazyk: angličtina
Zdroj: Neurochemical research [Neurochem Res] 2024 Oct; Vol. 49 (10), pp. 2668-2681. Date of Electronic Publication: 2024 Jun 26.
DOI: 10.1007/s11064-024-04199-5
Abstrakt: Neuropsychiatric and neurological disorders pose a significant global health burden, highlighting the need for innovative therapeutic approaches. Fingolimod (FTY720), a common drug to treat multiple sclerosis, has shown promising efficacy against various neuropsychiatric and neurological disorders. Fingolimod exerts its neuroprotective effects by targeting multiple cellular and molecular processes, such as apoptosis, oxidative stress, neuroinflammation, and autophagy. By modulating Sphingosine-1-Phosphate Receptor activity, a key regulator of immune cell trafficking and neuronal function, it also affects synaptic activity and strengthens memory formation. In the hippocampus, fingolimod decreases glutamate levels and increases GABA levels, suggesting a potential role in modulating synaptic transmission and neuronal excitability. Taken together, fingolimod has emerged as a promising neuroprotective agent for neuropsychiatric and neurological disorders. Its broad spectrum of cellular and molecular effects, including the modulation of apoptosis, oxidative stress, neuroinflammation, autophagy, and synaptic plasticity, provides a comprehensive therapeutic approach for these debilitating conditions. Further research is warranted to fully elucidate the mechanisms of action of fingolimod and optimize its use in the treatment of neuropsychiatric and neurological disorders.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: